Vaccination in HIV-infected adults.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 4117268)

Published in AIDS Patient Care STDS on July 16, 2014

Authors

Nancy F Crum-Cianflone1, Mark R Wallace

Author Affiliations

1: 1 Infectious Disease Clinic, Naval Medical Center San Diego , San Diego, California.

Articles cited by this

(truncated to the top 100)

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet (2000) 4.23

Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst (2009) 3.58

Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis (2009) 3.12

Recent resurgence of mumps in the United States. N Engl J Med (2008) 2.90

Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis (2011) 2.86

Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis (1998) 2.82

Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis (2013) 2.58

Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance. CDC Meningitis Surveillance Group. Ann Intern Med (1992) 2.33

A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med (2010) 2.30

Influenza-associated morbidity and mortality in young and middle-aged women. JAMA (1999) 2.08

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS (2010) 2.03

Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med (2001) 2.03

Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2012) 1.98

Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS (2010) 1.87

Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA (2011) 1.83

2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2014) 1.81

Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis (1991) 1.75

Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS (1994) 1.61

Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis (2010) 1.52

Severe measles in immunocompromised patients. JAMA (1992) 1.52

Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine (2001) 1.52

Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med (2005) 1.50

Influenza in patients with human immunodeficiency virus infection. Chest (1990) 1.50

Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis (2011) 1.49

Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med (1988) 1.47

Occurrence of acute hepatitis A in patients infected with human immunodeficiency virus. Clin Infect Dis (2000) 1.45

Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine (2005) 1.44

The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr (2005) 1.38

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis (2010) 1.37

Measles in the United States during the postelimination era. J Infect Dis (2010) 1.36

Immunization of HIV-infected children with varicella vaccine. J Pediatr (2001) 1.35

Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr (2010) 1.35

The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA (1989) 1.32

Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis (2000) 1.32

Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis (2007) 1.25

Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine (2008) 1.24

Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine (2000) 1.23

Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr (2005) 1.22

Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis (2006) 1.17

Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1999) 1.16

Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis (2005) 1.14

Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis (2010) 1.14

Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med (2013) 1.14

Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006. Pediatrics (2007) 1.14

Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine (2000) 1.13

CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis (2008) 1.13

Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis (1995) 1.11

Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine (2009) 1.11

Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS (2007) 1.11

Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis (2004) 1.11

Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics (2001) 1.10

A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis (2010) 1.10

Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis (2014) 1.06

Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis (2007) 1.06

Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis (2013) 1.05

Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine (2011) 1.04

Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb Mortal Wkly Rep (1996) 1.03

23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS (2004) 1.03

Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand. Hum Vaccin Immunother (2013) 1.02

Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis (2006) 1.01

Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS (2012) 1.01

Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet (1994) 1.00

Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med (1998) 1.00

Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis (2000) 0.98

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J (2001) 0.98

Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis (2008) 0.97

Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J (2010) 0.97

Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med (2014) 0.97

Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis (2009) 0.97

Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis (2012) 0.95

Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine. BMC Infect Dis (2006) 0.95

Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS (2009) 0.95

A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis (2008) 0.94

Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis (2004) 0.93

Notes from the field: serogroup C invasive meningococcal disease among men who have sex with men - New York City, 2010-2012. MMWR Morb Mortal Wkly Rep (2013) 0.93

Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART. Vaccine (2009) 0.93

Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr (2012) 0.92

Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev (2009) 0.91

Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr (2008) 0.90

Varicella immunity and clinical disease in HIV-infected adults. South Med J (1994) 0.90

Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai (2002) 0.90

Predictors of influenza vaccination in HIV-infected patients in the United States, 1990-2002. J Infect Dis (2007) 0.89

Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis (2003) 0.89

Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis (2001) 0.89

Disseminated meningococcal infection in HIV-seropositive patients. AIDS (1993) 0.89

Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients. AIDS Res Hum Retroviruses (2005) 0.88

Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis (2011) 0.88

Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi). Vaccine (1999) 0.86

Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat (2007) 0.85

Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS (2000) 0.85

Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine (2004) 0.85

Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2014. Ann Intern Med (2014) 0.85

Invasive Haemophilus influenzae infections in men with HIV infection. JAMA (1992) 0.84

Impact of a new vaccine clinic on hepatitis B vaccine completion and immunological response rates in an HIV-positive cohort. J Infect Public Health (2013) 0.84

Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. Pediatr Infect Dis J (2012) 0.84

Isolated antibody to hepatitis B core antigen in HIV-1 infected patients and a pilot study of vaccination to determine the anamnestic response. J Med Assoc Thai (2006) 0.83

The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis. Am J Epidemiol (2010) 0.82

Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali. Trans R Soc Trop Med Hyg (2012) 0.82

Articles by these authors

Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr (2006) 5.87

Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med (2006) 2.26

Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer (2005) 2.09

Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine (Baltimore) (2004) 1.69

Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother (2010) 1.47

Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) (2005) 1.46

Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. AIDS (2003) 1.34

Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat Biotechnol (2003) 1.32

Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. Arch Neurol (2003) 1.22

Erectile dysfunction and hypogonadism among men with HIV. AIDS Patient Care STDS (2007) 1.08

A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. AIDS Patient Care STDS (2005) 1.07

Staphylococcus lugdunensis: an emerging pathogen. South Med J (2011) 0.99

Pneumonia outbreak associated with group a Streptococcus species at a military training facility. Clin Infect Dis (2005) 0.98

Gordonia bronchialis sternal wound infection in 3 patients following open heart surgery: intraoperative transmission from a healthcare worker. Infect Control Hosp Epidemiol (2012) 0.97

Graves disease: an increasingly recognized immune reconstitution syndrome. AIDS (2006) 0.95

Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis (2002) 0.94

Stenotrophomonas maltophilia endocarditis. Scand J Infect Dis (2002) 0.93

Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy. AIDS (2006) 0.91

HIV-specific immunity during structured antiviral drug treatment interruption. Vaccine (2003) 0.91

Upper respiratory tract infections (URI). Mil Med (2004) 0.89

Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis (2011) 0.88

Group B streptococcal necrotizing fasciitis and toxic shock-like syndrome: a case report and review of the literature. Scand J Infect Dis (2003) 0.87

Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis (2004) 0.87

Correlates of human herpesvirus-8 seropositivity among U.S. military members recently infected with human immunodeficiency virus. Sex Transm Dis (2003) 0.87

Infectious diseases consultation and the management of Staphylococcus aureus bacteremia. Clin Infect Dis (2013) 0.85

Halting a pneumococcal pneumonia outbreak among United States Marine Corps trainees. Am J Prev Med (2003) 0.84

Puerperal group a streptococcal infections: a case series and discussion. Case Rep Med (2013) 0.82

Vaccination in patients with HIV infection. Curr Infect Dis Rep (2006) 0.79

Over-treatment of carbapenemase-producing Enterobacteriaceae. Scand J Infect Dis (2011) 0.79

Unintended smallpox vaccination of HIV-1-infected individuals in the United States military. Clin Infect Dis (2004) 0.77

A cluster of disseminated coccidioidomycosis cases at a US military hospital. Mil Med (2003) 0.77

HIV care in the U.S. Navy: a multidisciplinary approach. Mil Med (2005) 0.77

Commentary on "Medical care of pregnant women in eastern North Carolina with human immunodeficiency virus". South Med J (2013) 0.75

Protecting the health of United States military forces in Afghanistan: applying lessons learned since the Gulf War. Clin Infect Dis (2002) 0.75

Infectious diarrhea in history. Infect Dis Clin North Am (2004) 0.75

Infectious causes of death in the medical examiner's office. Am J Forensic Med Pathol (2015) 0.75

Drug-resistant Streptococcus pneumoniae in a day care population. Clin Infect Dis (2002) 0.75

Risk factors for Helicobacter pylori resistance. Curr Gastroenterol Rep (2002) 0.75

"Real world' treatment of hepatitis C. Curr Gastroenterol Rep (2002) 0.75

New issues in infectious diarrhea. Rev Gastroenterol Disord (2005) 0.75

Diagnosis and treatment of bacterial diarrhea. Curr Gastroenterol Rep (2003) 0.75

A case series of group A Streptococcus necrotizing fasciitis in military trainees. Mil Med (2004) 0.75

Treatment of acute hepatitis C. Curr Gastroenterol Rep (2002) 0.75

The effect of driving distance from medical treatment facility and short-term management outcomes in Department of Defense beneficiaries newly diagnosed with human immunodeficiency virus. Mil Med (2003) 0.75

Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated? J Acquir Immune Defic Syndr (2006) 0.75

How to Monitor and Advise Vegans to Ensure Adequate Nutrient Intake. J Am Osteopath Assoc (2016) 0.75

Are Low-Carbohydrate Diets Safe and Effective? J Am Osteopath Assoc (2016) 0.75